Elevance Health Inc. (ELV) Tops Q2 EPS by 124c, raises guidance

Elevance Health Inc. (NYSE: ELV) reported Q2 EPS of $7.45, $1.24 better than the analyst estimate of $6.21. Revenue for the quarter came in at $49.8 billion versus the consensus estimate of $48.63 billion.

GUIDANCE:

Elevance Health Inc. sees FY2026 EPS of at least $27.00, versus the consensus of $26.91.

For earnings history and earnings-related data on Elevance Health Inc. (ELV) click here.

You May Also Be Interested In

• HSBC starts SpaceX at Hold, sees execution risks tempering long-term AI ambitions
• Intel (INTC) PT Raised to $100 at DA Davidson Following Strong Q2 Results
• Noodles & Company (NDLS) Tops Q2 EPS by 26c ; Offers Guidance